The process is often imagined as a single, sudden 'aha!' moment. It’s much more like building a massive, intricate structure—a colossal puzzle that represents all medical knowledge. Every time a treatment is approved, a new piece of the puzzle clicks into place. 

Despite advances in cancer treatment in recent years, five-year survival rates for acute myeloid leukemia (AML) remain low at just 30% on average, according to the National Cancer Institute. Factors in the development of AML are diverse with many different drivers. A longtime goal for scientists in this field is finding a single drug that can treat all types of AML.

  The University of Texas Health Science Center at San Antonio (UT Health San Antonio) received more than $3.19 million in new academic research awards as part of the latest $68 million funding round announced on February 19 by the Cancer Research Prevention Institute of Texas (CPRIT). The state agency, which focuses on the fight […]

San Antonio has one of the highest rates of metabolic dysfunction-associated steatotic liver disease (MASLD) in the United States, largely driven by high rates of obesity and diabetes in the region. This chronic liver condition can lead to serious health conditions including severe liver fibrosis or cirrhosis and liver cancer, posing a significant public health […]